Skip to content

IEMbase 0340: SLC35A1-related CMP-sialic acid transporter deficiency

Scope

Field Value
IEMbase ID 340
Nosology 18.4.01.01
Gene SLC35A1
External IDs OMIM:603585; ORPHA:238459
Generated mapping UNMAPPED; low-score candidate SLC35A2-CDG.yaml
Candidate DisMech targets Reject SLC35A2-CDG.yaml as a disease mapping
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents SLC35A1-CDG/CDG-IIf, caused by CMP-sialic acid transporter deficiency. Characteristic rows include ataxia, bleeding tendency, epilepsy, intellectual disability, and macrothrombocytopenia. Additional clinical rows include behavioral disorder, hypotonia, and microcephaly.

The biochemical rows include serum N-glycans, type II sialotransferrins, and altered sialylation of platelet glycoproteins. No treatment rows are present.

DisMech phenotype coverage

The generated SLC35A2-CDG candidate is a close family/pathway neighbor but not a valid disease target. SLC35A2-CDG models an X-linked UDP-galactose transporter defect with hypogalactosylation, developmental and epileptic encephalopathy, SLC35A2 brain mosaicism, and D-galactose supplementation. SLC35A1-CDG instead involves CMP-sialic acid transport, platelet glycoprotein sialylation, macrothrombocytopenia, and bleeding tendency.

No standalone SLC35A1-CDG entry exists locally.

Concordance and completeness

Judgement: true local disease gap; reject SLC35A2-CDG as the mapping target.

Both disorders are nucleotide-sugar-transporter CDGs, but they differ by gene, donor substrate, inheritance pattern, and key phenotype. SLC35A2 is useful context for transporter-CDG modeling only.

Curation actions

  • Add a standalone SLC35A1-CDG target before treating this record as mapped.
  • Do not map to SLC35A2-CDG based only on the shared transporter/CDG family.
  • Preserve macrothrombocytopenia, bleeding tendency, ataxia, epilepsy, microcephaly, platelet glycoprotein sialylation, serum N-glycans, and type II sialotransferrins as future-curation prompts.